Literature DB >> 11672453

17 beta-Hydroxysteroid dehydrogenase type 2 expression and enzyme activity in the human gastrointestinal tract.

T Sano1, G Hirasawa, J Takeyama, A D Darnel, T Suzuki, T Moriya, K Kato, H Sekine, S Ohara, T Shimosegawa, J Nakamura, M Yoshihama, N Harada, H Sasano.   

Abstract

The 17 beta-hydroxysteroid dehydrogenases (17 beta HSDs) play an important role in the regulation of intracellular levels of biologically active sex steroid hormones in various human tissues. To date, eight distinctive 17 beta HSD enzymes have been cloned and characterized in humans. Among these isoenzymes, 17 beta HSD type 2 (17 beta HSD2) catalyses the conversion of testosterone into androstenedione and/or oestradiol into oestrone in various tissues, and it has thus been suggested to be involved in the biological inactivation of these sex steroids. The human gastrointestinal tract and liver are considered as the principle sites of inactivation and metabolism of various forms of orally administered sex steroids. We therefore examined 17 beta HSD2 expression and activity in human adult non-pathological gastrointestinal tract in order to clarify further the biological significance of this enzyme. A total of 80 specimens (40 from males and 40 from females) of normal oesophageal, stomach, duodenal, ileal, colonic and rectal tissues were examined for immunohistochemistry. Altogether, 17 tissue specimens were used for enzyme assay, and eight for RNA analysis. 17 beta HSD2 activity was detected in the stomach, duodenum, ileum, colon and rectum. 17 beta HSD2 mRNA was most abundant in the small intestine. 17 beta HSD2 immunoreactivity was localized almost exclusively to the absorptive epithelium, which may be involved in the inactivation of excessive endogenous and exogenous active sex steroids. Results from the present study thus suggest that the human gastrointestinal tract is an important sex steroid metabolizing organ in humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11672453

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  6 in total

1.  Molecular cloning and expression of 17β-hydroxysteroid dehydrogenase type 2 gene in Hu sheep.

Authors:  Chang Long Wang; Shi Jia Ying; Zi Yu Wang; Hui Jun Xing; Li Zhong Wang; Dong Yang He; Shen Hua Xiao; Feng Wang
Journal:  Mol Biol Rep       Date:  2012-10-25       Impact factor: 2.316

2.  Quantitative characterization of UDP-glucuronosyltransferase 2B17 in human liver and intestine and its role in testosterone first-pass metabolism.

Authors:  Haeyoung Zhang; Abdul Basit; Diana Busch; King Yabut; Deepak Kumar Bhatt; Marek Drozdzik; Marek Ostrowski; Albert Li; Carol Collins; Stefan Oswald; Bhagwat Prasad
Journal:  Biochem Pharmacol       Date:  2018-08-04       Impact factor: 5.858

3.  Placenta defects and embryonic lethality resulting from disruption of mouse hydroxysteroid (17-beta) dehydrogenase 2 gene.

Authors:  Pia Rantakari; Leena Strauss; Riku Kiviranta; Heidi Lagerbohm; Jenni Paviala; Irma Holopainen; Seppo Vainio; Pirjo Pakarinen; Matti Poutanen
Journal:  Mol Endocrinol       Date:  2007-11-29

4.  Effect of Dose and 5α-Reductase Inhibition on the Circulating Testosterone Metabolite Profile of Men Administered Oral Testosterone.

Authors:  Abdul Basit; John K Amory; Bhagwat Prasad
Journal:  Clin Transl Sci       Date:  2018-06-19       Impact factor: 4.689

5.  Proteomic analysis of lipid droplets from Caco-2/TC7 enterocytes identifies novel modulators of lipid secretion.

Authors:  Frauke Beilstein; Julien Bouchoux; Monique Rousset; Sylvie Demignot
Journal:  PLoS One       Date:  2013-01-02       Impact factor: 3.240

6.  The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers.

Authors:  S P Newman; P A Foster; Y T Ho; J M Day; B Raobaikady; P G Kasprzyk; M P Leese; B V L Potter; M J Reed; A Purohit
Journal:  Br J Cancer       Date:  2007-11-20       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.